Research Institute of General Surgery, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Hepatobiliary Pancreat Dis Int. 2009 Aug;8(4):345-50.
Multivisceral transplantation (MVTx) is concurrent transplantation of the stomach, spleen, pancreaticoduodenal complex, and intestine, with (MVTx) or without (modified MVTx) the liver. MVTx has been performed more frequently worldwide, and the survival of patients approximates that of patients who have undergone transplantation of other solid organs. This review introduces the recent development in MVTx.
Two English-language medical databases, MEDLINE and SPRINGERLINK, were searched for articles on "multivisceral transplantation", "graft procurement", "immunosuppression", and related topics.
MVTx has been the optimal therapy for the intestine with liver failure and/or failure of several other organs, despite many difficulties in preventing rejection and infection.
Further study is needed to improve the long-term survival of recipients and reduce the complications.
多器官联合移植(MVTx)是指同时移植胃、脾、胰十二指肠复合体和肠,可伴有(MVTx)或不伴有(改良 MVTx)肝脏。MVTx 在全球范围内的应用越来越频繁,患者的存活率与接受其他实体器官移植的患者相近。本综述介绍了 MVTx 的最新进展。
在 MEDLINE 和 SPRINGERLINK 两个英文医学数据库中,检索了关于“多器官联合移植”、“移植物获取”、“免疫抑制”和相关主题的文章。
尽管在预防排斥和感染方面存在诸多困难,但 MVTx 仍然是肝衰竭和/或多个其他器官衰竭的肠道的最佳治疗方法。
需要进一步研究以提高受者的长期生存率并减少并发症。